Towards Early and More Specific Diagnosis of Prostate Cancer Towards Early and More Specific Diagnosis of Prostate Cancer? Beyond PSA: New Biomarkers Ready for Prime Time  Jack A. Schalken  European Urology Supplements  Volume 8, Issue 3, Pages 97-102 (January 2009) DOI: 10.1016/j.eursup.2008.10.007 Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 1 Percentage of men with positive biopsy versus prostate cancer gene 3 score range. The number of men in each group is shown in parentheses. European Urology Supplements 2009 8, 97-102DOI: (10.1016/j.eursup.2008.10.007) Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 2 Receiver operating characteristic curves for serum prostate-specific antigen (PSA), prostate cancer gene 3 (PCA3) score, and the logistic regression model incorporating serum PSA, PCA3 score, diagnostic digital rectal examination result, and prostate gland volume. PSA=prostate-specific antigen; AUC=area under the curve; PCA3=prostate cancer gene 3; LR=logistic regression; TRUSVol=transrectal ultrasound volume; DRE=digital rectal examination. European Urology Supplements 2009 8, 97-102DOI: (10.1016/j.eursup.2008.10.007) Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 3 Mean prostate cancer gene 3 scores for men with low-volume/low-grade prostate cancer (<0.5cc, Gleason 6) versus significant prostate cancer (>0.5cc, Gleason ≥7). Error bars represent the standard error of the mean. PCa=prostate cancer. Reprinted from The Journal of Urology, Vol. 179(5), Nakanishi H, Groskopf J, Fritsche HA, et al, PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance, Pages 1804–10, Copyright (2008), with permission from The American Urological Association. European Urology Supplements 2009 8, 97-102DOI: (10.1016/j.eursup.2008.10.007) Copyright © 2008 European Association of Urology Terms and Conditions